AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
1.230
+0.175 (16.59%)
Feb 5, 2026, 12:38 PM EST - Market open
AIM ImmunoTech Employees
As of December 31, 2024, AIM ImmunoTech had 23 total employees, including 21 full-time and 2 part-time employees. The number of employees decreased by 5 or -17.86% compared to the previous year.
Employees
23
Change (1Y)
-5
Growth (1Y)
-17.86%
Revenue / Employee
$4,870
Profits / Employee
-$684,783
Market Cap
3.51M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 23 | -5 | -17.86% | 21 | 2 |
| Dec 31, 2023 | 28 | 4 | 16.67% | 26 | 2 |
| Dec 31, 2022 | 24 | 1 | 4.35% | 22 | 2 |
| Dec 31, 2021 | 23 | 0 | - | 21 | 2 |
| Dec 31, 2020 | 23 | -3 | -11.54% | 21 | 2 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Jaguar Health | 49 |
| HCW Biologics | 36 |
| Scinai Immunotherapeutics | 31 |
| Lyra Therapeutics | 30 |
| Artelo Biosciences | 5 |
| Oragenics | 5 |
| CNS Pharmaceuticals | 5 |
| SciSparc | 2 |
AIM News
- 4 hours ago - AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer - GlobeNewsWire
- 12 days ago - AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering - GlobeNewsWire
- 2 months ago - AIM ImmunoTech to Participate in Live ‘Fireside' Chat on Virtual Investor Closing Bell Series - GlobeNewsWire
- 2 months ago - AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program - GlobeNewsWire
- 3 months ago - Aimia Inc. (AIM:CA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer - GlobeNewsWire
- 3 months ago - AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting - GlobeNewsWire
- 3 months ago - AIM ImmunoTech to Attend the 2025 Maxim Growth Summit - GlobeNewsWire